Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
- PMID: 32931711
- PMCID: PMC7737584
- DOI: 10.1164/rccm.202007-2913LE
Reply to Rappaport et al.: Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19
Comment on
-
Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.Am J Respir Crit Care Med. 2020 Dec 15;202(12):1731-1733. doi: 10.1164/rccm.202006-2511LE. Am J Respir Crit Care Med. 2020. PMID: 32931713 Free PMC article. No abstract available.
Similar articles
-
Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.Am J Respir Crit Care Med. 2020 Dec 15;202(12):1731-1733. doi: 10.1164/rccm.202006-2511LE. Am J Respir Crit Care Med. 2020. PMID: 32931713 Free PMC article. No abstract available.
-
Intermediate dose thromboprophylaxis in SARS-CoV-2 related venous thrombo embolism.Eur J Intern Med. 2021 Jun;88:141-143. doi: 10.1016/j.ejim.2021.03.025. Epub 2021 Mar 26. Eur J Intern Med. 2021. PMID: 33820684 Free PMC article. No abstract available.
-
Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate.Medicina (Kaunas). 2020 Sep 27;56(10):506. doi: 10.3390/medicina56100506. Medicina (Kaunas). 2020. PMID: 32992511 Free PMC article.
-
Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines.Swiss Med Wkly. 2020 Jun 21;150:w20301. doi: 10.4414/smw.2020.20301. eCollection 2020 Jun 15. Swiss Med Wkly. 2020. PMID: 32640479
-
Plasma anti-FXa level as a surrogate marker of the adequacy of thromboprophylaxis in critically ill patients: A systematic review.Thromb Res. 2016 Mar;139:10-6. doi: 10.1016/j.thromres.2015.12.016. Epub 2016 Jan 4. Thromb Res. 2016. PMID: 26916290
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical